STOCK TITAN

Executive at Charles River (NYSE: CRL) awarded 1,797 performance shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Charles River Laboratories International executive Mark Mintz, EVP and Chief Information Officer, reported equity compensation activity in company stock. On January 30, 2026, he acquired 1,797 shares of common stock at $0, issued after meeting performance goals from performance share unit awards granted on May 26, 2023. On the same date, 655 shares of common stock were disposed of at $211.68 per share under transaction code F. Following these transactions, Mintz directly owned 7,492 shares of Charles River common stock.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mintz Mark

(Last) (First) (Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE ST

(Street)
WILMINGTON MA 01887

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Information Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/30/2026 A 1,797(1) A $0 8,147 D
Common Stock 01/30/2026 F 655 D $211.68 7,492 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.
/s/ Mark Mintz 02/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did CRL executive Mark Mintz report?

Mark Mintz reported two transactions in CRL common stock on January 30, 2026. He acquired 1,797 shares at $0 and disposed of 655 shares at $211.68, ending with 7,492 shares directly owned.

Who is the insider involved in this Charles River Laboratories (CRL) Form 4 filing?

The Form 4 filing involves Mark Mintz, Executive Vice President and Chief Information Officer of Charles River Laboratories International, Inc. He reported acquisitions and dispositions of CRL common stock, resulting in direct ownership of 7,492 shares after the reported transactions.

How many CRL shares did Mark Mintz acquire through performance awards?

Mark Mintz acquired 1,797 shares of Charles River Laboratories common stock at $0. These shares were issued after achievement of performance goals in performance share unit awards originally granted on May 26, 2023, increasing his direct holdings before the subsequent disposition.

What does the disposal transaction in Mark Mintz’s CRL Form 4 show?

The Form 4 shows a disposal of 655 shares of Charles River Laboratories common stock on January 30, 2026. The transaction used code F, with a price of $211.68 per share, and left Mintz with 7,492 directly owned shares afterward.

How many Charles River (CRL) shares does Mark Mintz own after these transactions?

After the reported January 30, 2026 transactions, Mark Mintz directly owns 7,492 shares of Charles River Laboratories common stock. This reflects both the 1,797-share issuance at $0 and the 655-share disposal at $211.68 recorded on the Form 4.
Charles Riv Labs Intl Inc

NYSE:CRL

CRL Rankings

CRL Latest News

CRL Latest SEC Filings

CRL Stock Data

10.36B
48.70M
1%
105.66%
5.42%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON